Pretest results indicated that the APs had prior knowledge of genetic testing to inform practice, primarily of BRCA1, BRCA2, HER/ErbB, and Oncotype DX as indicated by write-in responses to questions A, B, C, and D. Contrary to tumor-centered testing, participants reported limited clinical experience with or education regarding patients’ genomic variations affecting medication efficacy in the breast cancer setting. Here, BRCA1 is linked to breast cancer.